Vivos Therapeutics, Inc.
VVOSNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M |
| Operating income | −$19.9M | −$11.2M | −$17.3M | −$25.0M | −$20.4M | −$12.0M |
| Net income | −$21.2M | −$11.1M | −$13.6M | −$23.8M | −$20.3M | −$12.1M |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M | $25.3M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M | $8.4M |
| Equity | −$1.5M | $8.0M | $411,000 | $4.8M | $25.5M | $16.9M |
| EPS (diluted) | $-2.07 | $-2.22 | $-11.14 | $-25.90 | $-0.96 | — |
| Shares out. | 5.9M | 2.7M | 29.7M | 23.0M | 18.2M | 18.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −114.1%
- Net margin
- −121.4%
- Return on equity
- 1420.8%
- Return on assets
- −84.2%
- Return on capital (ROCE)
- −281.1%
- Liabilities / assets
- 106.2%
- Debt / equity
- —
- Book value / share
- $-0.25
- Revenue growth (YoY)
- 16.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -25.19distress
- Accruals / assets
- −23.5%clean
- Beneish M-Score
- -1.42elevated
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Qmissed a reporting deadline ↗May 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2026
- V-Co Investors 3 LlcActivist (13D)Apr 2, 2026
- Luo DaweiPassive (13G)Jul 14, 2025
- V-Co Investors LlcActivist (13D)Jun 16, 2025
- Intracoastal Capital, LlcPassive (13G)Dec 30, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Skaff Michael C10% owner | Mar 31, 2026 | Buy | 1.0M | $1.34 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 978,065 | 6.4 | +36.6% |
| Apr 30, 2026 | 716,108 | 2.1 | +29.3% |
| Apr 15, 2026 | 554,017 | 1.3 | +75.3% |
| Mar 31, 2026 | 316,118 | 2.7 | -34.7% |
| Mar 13, 2026 | 484,373 | 4.3 | +1.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeApr 22, 2026
- Results of operationsApr 15, 2026
- Entered a material agreement · Unregistered equity saleApr 3, 2026
- Director / officer changeFeb 6, 2026
- Entered a material agreement · Unregistered equity saleJan 20, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleJan 16, 2026
- Other material eventDec 17, 2025
- Entered a material agreement · New financial obligationDec 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.